

# eve

HEALTH GROUP

---

## NEXTRACT ACQUISITION

29 MAY 2025 SHAREHOLDER MEETING

REFORMULATING A PROVEN DRUG TARGETING

THE \$5.3B ERECTILE DYSFUNCTION MARKET

ENHANCED SOLUBILITY DESIGNED FOR FASTER ACTION AND HIGHER EFFICACY

# Important Notice and Disclaimer

This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

You should not act or refrain from acting in reliance on this presentation material. This overview of Eve Health Group Limited does not purport to be all inclusive or to contain all information that its recipients may require in order to make an informed assessment of the Company's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation and making any investment decision.

Eve Health Group Limited has not verified the accuracy or completeness of the information, statements and opinions contained in this presentation. Accordingly, to the maximum extent permitted by law, the Company makes no representation and give no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

This presentation contains forward-looking statements regarding the Company's intentions and future business, including the future business of its subsidiaries. These statements reflect current information, expectations, intentions and strategies regarding the future, and are subject to certain risks and uncertainties. Should one or more of these risks or uncertainties materialise, or should any of the underlying assumptions prove incorrect, actual results may vary from the expectations, intentions and strategies described in this presentation. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Other than where required by law, the Company is under no obligation to revise any forward-looking statement to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

All product-related statements in this presentation reflect formulation design intent, or anecdotal user-reported outcomes from early-stage evaluations. These statements are not intended to imply proven clinical efficacy or therapeutic equivalence to existing products. Clinical trials and regulatory assessments are ongoing or pending, and outcomes are subject to change. Investors should not rely on forward-looking statements as guarantees of future performance.

*Authorised for release* - This announcement was authorised for release by Bill Fry, Managing Director.

# Executive Summary

**Eve Health Overview:** Eve Health Group specialises in innovative health solutions, enhancing patient care across various medical sectors. It currently owns Meluka Australia which targets gut health and generated approximately \$1.9m in revenue in Australian DTC sales in FY24.

**Nextract Acquisition:** Nextract improves treatment of sexual and reproductive health for men and women starting with erectile dysfunction (ED) and dysmenorrhea (period pain).



**Repurposed Pharmaceutical Drugs** by improving the solubility of already proven formulations Nextract's products improve the speed to effectiveness to be best in market.



**Products for ED and dysmenorrhea have been developed** and are currently undergoing stability studies ahead of submission to the TGA for approval. Product efficacy and manufacturing processes are already in place.



Disrupting the **US\$5.3<sup>1</sup> billion ED and US\$10.9<sup>2</sup> billion Dysmenorrhea global markets.**



**Rapid Path to Commercialisation in Australia** with regulatory approval expected within 3-6 months following submission and first sales commencing immediately following manufacture via SAS-B channel. Sales expected to commence by Q1 2026.



**Market Position Advantage:** Nextract occupies a pivotal market role with broad experience in navigating regulatory approvals. Nextract offers unique products that complement Eve Health's existing offerings and can elevate these products to delivering a broad range of commercialised medical solutions within a short period of time.

# The Market Demand for ED Solutions



**40%**<sup>1</sup>

of men at age 40

**70%**

of men at age 70



Phosphodiesterase 5 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagra, Cialis, Levitra

**60% -70%**<sup>2</sup>

Patients report a positive outcome

Up to **60 min**

Response time for PDE5Is

**50%**

Patients stop purchasing PDE5Is



**USD 5.3b**<sup>3</sup>

Market Size 2025

**7.6%**

CAGR from 2025 - 2032



**322m**<sup>4</sup>

Men globally are projected to be affected by erectile dysfunction in 2025

Men that are impacted by erectile dysfunction



USA

**30m**



CHINA

**150m**



AUSTRALIA

**8m**

<sup>1</sup> Feldman et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61, January 1994

<sup>2</sup> Carvalho et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation," Journal of Sexual Medicine, May 2012.

<sup>3</sup> Coherent Market Insights - <https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200>

<sup>4</sup> Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023

# The Nextract ED Solution

**Proprietary Solubility Technology:** Nextract's proprietary nanoemulsion platform is designed to enhance solubility and bioavailability.<sup>2</sup>

**Nextract Research:** Solubilised PDE5Is.

**Solubilised Advantage:** Nextract's formulation aims to improve absorption of Tadalafil, with an intended effective dose of 10mg.<sup>2</sup>

**Nextract Formulation** approach is intended to support improved mucosal absorption and onset.<sup>2</sup>

**Solutions:** Oral breath freshening strip, chewing gum and gummies.

## PRODUCT

## TIME TO EFFECTIVENESS

### Nextract

5 – 15 minutes<sup>1</sup>

**Viagra**  
(Sildenafil)

30 – 60 minutes

**Cialis**  
(Tadalafil)

30 – 60 minutes

**Levitra**  
(Vardenafil)

25 – 60 minutes

## KEY TARGETS

**100%<sup>1</sup>**

Effectiveness from  
60% - 70% with Tadalafil<sup>1</sup>

**< 10 min**


Time to effect from  
+/- 60 min with Tadalafil

<sup>1</sup> Based on formulation design, known compound properties, and a 10-person observational study, where all participants responded within 15 minutes to a 10mg Tadalafil oral film. Comparator data from published averages. Clinical validation pending.

<sup>2</sup> Preliminary claims supported by Provisional Patent Application No. 2024902673 (IP Australia), describing a nanoemulsion-based transmucosal delivery platform intended to improve solubility and absorption. Clinical validation pending.

# Product Pipeline and Development Timeline

## ED Solution



<sup>1</sup> Timetable for SAS-B is typically 2 to 3 working days

Overall timelines are indicative and subject to regulatory approvals and may differ from the above.



# Path to Market



**Regulatory Fast-Tracking in Australia:** TGA access pathways for potentially faster commercialisation via (i) SAS-B<sup>1</sup>, (ii) Authorised Prescriber, (iii) ARTG Export Only. These frameworks enable expedited access for innovative therapies for unmet clinical need. Vital for timely market entry.



**US Regulatory Pathways:** The FDA 505(b)(2) application offers a streamlined approval for Nextra products, potentially enabling earlier commercialisation in the US market.



**Importance of Regulatory Approval:** Successful navigation of regulatory processes assures investors of reduced time-to-market and enhanced revenue potential.



# The Nextract Dysmenorrhea Solution

**Addressable Market:** Global market size of US\$10.9b<sup>1</sup> in 2024

**Proprietary Solubility Technology:** Nextract's formulation is designed to enhance solubility and support rapid absorption through a proprietary nanoemulsion-based delivery platform.<sup>3</sup>

**Nextract Research & Formulation:** Dysmenorrhea pain relief with reduced potential for adverse effects and improved bioavailability for prompt pain relief.

**Solution:** gelcap and gummies.

**Pathway to Market:** Similar to ED product however sales can commence as soon as it's submitted to the TGA.

PRODUCT	TIME TO EFFECTIVENESS
<b>Nextract</b>	5 – 15 minutes <sup>2</sup>
<b>NSAID</b> (E.g. Ibuprofen, Naproxen)	30 – 60 minutes
<b>Hormonal Contraceptives</b> (E.g. Birth Control Pills, IUDs)	Several days to weeks


## KEY TARGETS

### Non-Hormonal

Naturally-derived products

### Fast Acting

Specifically formulated for improved uptake



### Reduced Adverse Effects

No hormones, no NSAIDs

<sup>1</sup> IMARC Group, Dysmenorrhea Market Outlook 2025-2035 - [www.imarcgroup.com/dysmenorrhea-market-outlook](https://www.imarcgroup.com/dysmenorrhea-market-outlook)

<sup>2</sup> Target onset and bioavailability are based on known properties of active compounds and preliminary formulation design. Further clinical validation is required. Data shown for comparator products is based on published average ranges.

<sup>3</sup> Note: Bioavailability and performance outcomes are subject to confirmation via clinical evaluation. Provisional Patent Application No. 2024902673 outlines nanoemulsion delivery for transmucosal absorption. Preliminary user outcomes suggest favourable onset profile; clinical validation is pending.



# Nextract Progress

**Nextract: On Track to Deliver Regulatory Approvals, Scalable Manufacturing and First Sales**

## Appointment of manufacturer partner



Nextract in discussions with pharma manufacturer partners. Preferred partner is expected to be decided by **CY Q3 2025**.

## Product development in final stages



Final stages R&D product development for Nextract ED products is expected to be completed in **CY Q3 2025**.

## TGA submission for exports



TGA submission and authorisation for export markets is expected in the early weeks of **CY Q4 2025**.

## Distribution Partner Australia



Australia first sales channels via easy online telehealth consults for fast home delivery **CY Q4 2025**.

## Target global markets



Middle East and North Africa (MENA) region a key target market, driven by strong demand for alcohol-free, patient-friendly formulations. Market size projected to grow to US\$167.5m by 2030.<sup>1</sup>

# Meluka Australia

**Meluka Australia Overview:** Meluka Australia is dedicated to delivering premium, taste-focused gut health solutions, leveraging the unique benefits of its proprietary *Lactobacillus rhamnosus* Beebiotic MAP01® strain.



Meluka Australia delivered **\$1.9m of annual revenue in FY24<sup>1</sup>** from its Australian DTC business.



Meluka Australia's range of tonics and powders are designed to support both **general gut wellbeing** and **specific digestive health concerns**, offering targeted solutions backed by innovation and research.



Meluka's established e-commerce, customer base, and wellness brand platform will **accelerate Nextra's product launch** and consumer education efforts.



Meluka Australia's **number 1 SKU, P3 Gut Builder** is a **triple-action postbiotic tonic** formulated for maximum bioavailability, delivering rapid absorption and gut health benefits. With a high product loyalty and consumer trust, **8 out of 10** rated it **5 stars<sup>2</sup>**, while **9 out of 10** reported noticeable improvement **within just 1 month<sup>3</sup>**.



# Directors and Management



**DAMIAN  
WOOD**

**PROPOSED  
MANAGING DIRECTOR**

Damian is a registered industrial pharmacist with experience as a frontline hospital clinician, pharmaceutical manufacturer, and business development lead.



**Dr STUART  
GUNZBURG**  
**CSO**

Stuart has a PHD specialising in drug formulation and solubility science. His work focuses on nano-emulsion drug delivery technology to optimise absorption.



**ROD  
HANNINGTON**  
**NON-EXECUTIVE CHAIRMAN**

Rod has over 25 years of experience working across FMCG and healthcare start-ups. He has held a variety of board roles at ASX-listed companies, with a particular focus in the consumer health space.



**BILL  
FRY**

**CURRENT CEO /  
PROPOSED NON-  
EXECUTIVE DIRECTOR**

Bill has over 20 years corporate experience specialising in investment management, finance, project evaluation, development and management.



**BEN  
ROHR**  
**COO**

Ben is an experienced business leader with a track record of growing brands across international markets. He has deep expertise in the Food & Beverage, Health, and Technology sectors, with a particular focus on nutraceuticals and wellness. He has led businesses in both Australia and the US.



**STEVEN  
JACKSON**  
**COMPANY  
SECRETARY  
& CFO**

Steven has worked across a range of industries dealing with acquisitions, investment analysis and financing.



**CARLOS  
JIN**  
**NON-EXECUTIVE  
DIRECTOR**

Carlos has over 30 years experience working in foreign companies as well as Chinese state-owned enterprises, specifically in HR management and investment management



1/245 Churchill Ave, Subiaco WA 6008

+61 8 6465 5500

[info@evehealthgroup.com.au](mailto:info@evehealthgroup.com.au)

[WWW.EVEHEALTHGROUP.COM.AU](http://WWW.EVEHEALTHGROUP.COM.AU)

INSPIRED *by* NATURE,  
PASSION *for* WELLNESS.